NCT04164719View on ClinicalTrials.gov

Dose-Proportionality and Food Effect Study of TNX-102 SL

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

December 24, 2019

Study Completion Date

December 24, 2019

Conditions
Healthy Subjects
Interventions
DRUG

TNX-102 SL

Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them

Trial Locations (1)

G1P 0A2

Canada, Quebec, Québec

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT04164719 - Dose-Proportionality and Food Effect Study of TNX-102 SL | Biotech Hunter | Biotech Hunter